Clinical trials: Open Angle Glaucoma
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Glaucoma
POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma
This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.
- Trial name
- NCT02466399
- Testing
- POLAT-001, Latanoprost ophthalmic solution
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Peregrine Ophthalmic
Glaucoma, Glaucoma, Open Angle
AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
- Trial name
- NCT02036541
- Testing
- AqueSys XEN 45 Glaucoma Implant
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- AqueSys, Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy Study of Travoprost APS Versus TRAVATAN
A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00848536
- Testing
- Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution, Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
- Volunteers
- 371 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to DUOTRAV® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having…
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT01327599
- Testing
- Travoprost 0.004%+Timolol 0.5% ophthalmic solution
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in…
- Trial name
- NCT02730871
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of a Glaucoma Drug Delivery System
The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00824720
- Testing
- High Dose Device, Low Dose Device
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vistakon Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02247804
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 106 sites in United States, Australia and 12 more
- Volunteers
- 594 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular…
- Trial name
- NCT00945958
- Testing
- SPARC0913
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Glaucoma, Open Angle or Ocular Hypertension
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP…
- Trial name
- NCT01722604
- Testing
- brinzolamide 1% ophthalmic suspension, Azopt 1%
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002.
- Trial name
- NCT02143843
- Testing
- Bimatoprost
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma
Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.
- Trial name
- NCT02928289
- Testing
- VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- APOTUS (NCT02003534)
- Testing
- 0.15% Brimonidine Tartrate
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
Post Market Study of the InnFocus MicroShunt
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
- Trial name
- NCT02177123
- Testing
- InnFocus MicroShunt implantation
- Where
- 6 sites in France, Netherlands and 2 more
- Volunteers
- 107 people
- Sponsor
- InnFocus Inc.
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
- Trial name
- COMPARE (NCT02023242)
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Ivantis, Inc.